Skip to main content
. 2022 May 23;7(5):445–461. doi: 10.1016/j.jacbts.2022.03.003

Figure 2.

Figure 2

sJAM-A Exerts a Prothrombotic Effect

Synergistic effect of sJAM-AD1D2 (30 μg/mL) on ADP (10 μmol/L) induced platelet (A) CD62P surface expression, PAC-1 binding (n = 5). ∗∗P < 0.01; ##P < 0.01. (B) Aggregation (n = 5 with technical replicates). ∗∗P < 0.01. (C) Relative stages of platelets spreading on fibrinogen (n = 5) over time ±sJAM-AD1 (10 μg/mL) or sJAM-AD1D2 (30 μg/mL). Bar = 2 μm. (D) Kinetics of platelet spreading on fibrinogen, and sJAM-AD1D2 accelerating the process. (Di) SICM topography images of spreading platelets ±sJAM-AD1D2 (30 μg/mL). Bar = 3 μm. (Dii) The spreading area as a function of time. Spreading was quantified by the final spreading area (horizontal arrows) and spreading duration until 90% of final spreading area (vertical arrows). The relative initial spreading rate was determined by fitting the spreading area (solid traces) up to 60% of the relative area with a linear fit (dashed red line). (Diii) Spreading area, spreading duration, and relative initial spreading rate ±sJAM-AD1D2. Data show mean ± SEM for sJAM-AD1D2-treated (n = 11) and control platelets (n = 8). ∗P < 0.05; ∗∗P < 0.01 (Student’s t-test). (E) Thrombus coverage (n = 5) ±sJAM-AD1D2 (30 μg/mL). ∗∗P < 0.01. Bar = 50 μm. (F) Thrombus (platelets labelled with GP Ibβ-X488 appearing in green) build-up over time in smJAM-A (50 μg/mouse) and BSA-control (50 μg/mouse) administered mice (n = 5 mice/group). Bar diagram shows time to vessel occlusion ±smJAM-A. ∗∗P < 0.01. Data represent mean ± SEM. Abbreviations as in Figure 1.